Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 139

Results For "NABL"

2339 News Found

Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
News | November 14, 2022

Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%

Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers


Biocon Biologics features on ASIA IP ELITE List 2022
News | November 14, 2022

Biocon Biologics features on ASIA IP ELITE List 2022

This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list


Biogen appoints Christopher Viehbacher as President and CEO
People | November 11, 2022

Biogen appoints Christopher Viehbacher as President and CEO

Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies


Ayu Health receives US $27 million additional funding
News | November 11, 2022

Ayu Health receives US $27 million additional funding

The company is making its entry into the Hyderabad market through its unique asset-light business model


LANXESS to showcase Biosecurity Solutions at EuroTier 2022
News | November 10, 2022

LANXESS to showcase Biosecurity Solutions at EuroTier 2022

The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products


Solvay partners with Ostium in single-use surgical instruments material recycling
Sustainability | November 09, 2022

Solvay partners with Ostium in single-use surgical instruments material recycling

Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.


Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
News | November 07, 2022

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company


Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
News | November 07, 2022

Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%

H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY


SRL Diagnostics inaugurates an upgraded laboratory at Gurugram
Clinical Trials | November 03, 2022

SRL Diagnostics inaugurates an upgraded laboratory at Gurugram

The laboratory is equipped to perform high-volume diagnostic testing services